Introduction
The goal of this study is to investigate the association between diagnosis
and severity of coronary artery disease (CAD) and Asprosin level.
Methods
Patients diagnosed with CAD who underwent conventional coronary angiography
for the first time were included in the present study. The patients were
divided into four groups, each consisting of 20 individuals, as medical
group, single coronary lesion group, double coronary lesion group, and
multiple coronary lesions group. Serum Asprosin values and Gensini scores of
the groups were compared in terms of compliance.
Results
In this study, Asprosin values were found to be significantly higher in the
multiple coronary lesions group than in the medical, single coronary, and
double coronary lesion groups (
P
<0.05). In the double
coronary lesion group, Asprosin values were significantly higher
(
P
<0.05) than the in the medical and single coronary
lesion groups. It was also found that Asprosin values did not differ at
significant levels in the medical and single coronary lesion groups
(
P
>0.05). It was determined that the increases in
Asprosin values and Gensini scores were compatible with each other.
Conclusion
The present study showed that the increases in serum Asprosin levels, along
with the increases in the number of coronary arteries with critical
stenosis, might be a marker in diagnosing and determining the severity of
CAD.
BACKGROUND: The aim of the study was to investigate if there was a difference in injury in intra-abdominal viscera due to blunt abdominal trauma sustained by rats with empty or full stomach and to examine which viscera is affected most, based on the direction of the trauma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.